Expertise in
28
conditions

Dr. Kendrith M. Rowland

Oncology
Carle
602 W University Ave, 
Urbana, IL 
Expertise in
28
conditions
Carle
602 W University Ave, 
Urbana, IL 

Overview

Kendrith Rowland is an Oncologist practicing medicine in Urbana, Illinois.

Dr. Rowland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Colorectal Cancer, Paget Disease of the Breast, and Angiosarcoma.

He is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 42 clinical trials.

Graduate Institution

University Of Illinois College Of Med (Chi/peor/rock/chm-Urb)

Specialties

Oncology

Licenses

Internal Medicine in IL

Hospital Affiliations

Carle Hoopeston Regional Health Center
Kirby Medical Center
Carle Foundation Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Carle
602 W University Ave, Urbana, IL 61801
Other Locations
Carle Foundation Hospital
509 W University Ave, Urbana, IL 61801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

41 Clinical Trials

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Enrollment Status: Completed
Publish Date: August 25, 2026
Intervention Type: Biological, Radiation
Study Drug: Pembrolizumab
Study Phase: Phase 2
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Other
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
View 9 Less Clinical Trials

29 Total Publications

Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Engendering Reproductive Health Within Oncologic Survivorship Trial, ECOG-ACRIN E1Q11.
Journal: JCO oncology practice
Published: April 28, 2026
Similar Doctors
Expertise in
6
conditions
Dr. Connie M. Piccone
Hematology | Oncology
Expertise in
6
conditions
Dr. Connie M. Piccone
Hematology | Oncology
Referral may be required

Carle Foundation Hospital

611 W Park St, 
Urbana, IL 
 (0.1 miles away)
309-624-9856
Languages Spoken:
English
See accepted insurances

Connie Piccone is a Hematologist and an Oncologist practicing medicine in Urbana, Illinois. Dr. Piccone is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Hemolytic Anemia, and Gallbladder Removal.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Carle Foundation Hospital

509 W University Ave, 
Urbana, IL 
 (0.1 miles away)
217-383-3311
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vamsi Vasireddy is an Oncologist practicing medicine in Urbana, Illinois. Dr. Vasireddy is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Myelodysplastic Syndrome (MDS), Urothelial Cancer, and Nephrectomy.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Carle Foundation Hospital

509 W University Ave, 
Urbana, IL 
 (0.1 miles away)
217-383-3010
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Prem Sobti is an Oncologist practicing medicine in Urbana, Illinois. Dr. Sobti is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pleuropulmonary Blastoma, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Sobti is currently accepting new patients.

Frequently Asked Questions about Dr. Kendrith M. Rowland

How do I make an appointment with Dr. Kendrith M. Rowland?

You can book an appointment with Dr. Kendrith M. Rowland by calling their office at 217-383-3010. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kendrith M. Rowland a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kendrith M. Rowland is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kendrith M. Rowland specialize in?

While Dr. Kendrith M. Rowland is a Oncology, they have specific expertise in Breast Cancer, Colorectal Cancer, and Paget Disease of the Breast. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kendrith M. Rowland participate in research or clinical trials?

Yes. Dr. Kendrith M. Rowland has published 29 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Kendrith M. Rowland's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kendrith M. Rowland accept my insurance?

Dr. Kendrith M. Rowland accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 217-383-3010 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rowland's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 97 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile